OXB has launched a fast-track development and manufacturing service aimed at biotechs facing timeline constraints, significantly accelerating the pathway to GMP manufacturing for lentiviral (LV) and adeno-associated viral (AAV) vectors. This new offering can reduce the timeline for AAV vector GMP manufacture from approximately 15 months to as little as seven months, while lentiviral vector timelines can be shortened from 12-18 months to nine months. This acceleration is facilitated by OXB’s proprietary inAAVate™ and LentiVector™ platforms, which leverage high-performance, plug-and-play technologies and advanced analytics to streamline processes.

The significance of this development lies in its potential to enhance the competitive edge of biotech clients by enabling them to meet clinical and regulatory milestones more rapidly. By integrating vector design, production, purification, and fill-finish, OXB is addressing a common bottleneck in cell and gene therapy development. This expedited service not only supports faster access to transformative therapies for patients but also allows emerging companies to navigate financial constraints more effectively, thereby broadening their operational capabilities.

The introduction of OXB’s fast-track offering represents a pivotal shift in the development landscape for viral vectors, particularly for companies with limited time or resources. This innovation could reshape current research paradigms by reducing development timelines by up to 50%, potentially influencing drug development strategies and investment decisions in the biotechnology sector. By making advanced manufacturing technologies more accessible, OXB is positioning itself as a key player in facilitating the rapid advancement of cell and gene therapies towards clinical application.

Source: globenewswire.com